These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27851862)

  • 1. Pancreatic Cancer Cell Lysis by Cell-Penetrating Peptide-MAGE-A3-Induced Cytotoxic T Lymphocytes.
    Batchu RB; Gruzdyn OV; Qazi AM; Mahmud EM; Mostafa G; Weaver DW; Gruber SA
    JAMA Surg; 2016 Nov; 151(11):1086-1088. PubMed ID: 27851862
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.
    Batchu RB; Gruzdyn OV; Moreno-Bost AM; Szmania S; Jayandharan G; Srivastava A; Kolli BK; Weaver DW; van Rhee F; Gruber SA
    Vaccine; 2014 Feb; 32(8):938-43. PubMed ID: 24406390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
    Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
    J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
    Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
    JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the MAGE A3 antigen in pancreatic cancer.
    Cogdill AP; Frederick DT; Cooper ZA; Garber HR; Ferrone CR; Fiedler A; Rosenberg L; Thayer SP; Warshaw AL; Wargo JA
    Surgery; 2012 Sep; 152(3 Suppl 1):S13-8. PubMed ID: 22770803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic tumor antigens: diagnostic markers and targets for immunotherapy.
    Finn OJ
    Important Adv Oncol; 1992; ():61-77. PubMed ID: 1374733
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
    So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
    Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
    Bao L; Dunham K; Lucas K
    Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of dendritic cells with melanoma-associated antigen 3 for inducing cytotoxicity by cytotoxic T lymphocytes on bladder cancer BIU-87 cells.
    Li XZ; Han Y; Tian J; Ren X; Ma X; Ma M
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy with MAGE antigens.
    Coulie PG
    Suppl Tumori; 2002; 1(4):S63-5. PubMed ID: 12415826
    [No Abstract]   [Full Text] [Related]  

  • 12. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.
    Ma W; Vigneron N; Chapiro J; Stroobant V; Germeau C; Boon T; Coulie PG; Van den Eynde BJ
    Int J Cancer; 2011 Nov; 129(10):2427-34. PubMed ID: 21207413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human dendritic cells engineered to secrete interleukin-18 activate MAGE-A3-specific cytotoxic T lymphocytes in vitro.
    Fan X; Ye M; Xue B; Ke Y; Wong CK; Xie Y
    Immunol Invest; 2012; 41(5):469-83. PubMed ID: 22490235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
    Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular biology of lung cancer series].
    Hiret S; Senellart H; Bennouna J
    Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
    Ottaviani S; Colau D; van der Bruggen P; van der Bruggen P
    Cancer Immunol Immunother; 2006 Jul; 55(7):867-72. PubMed ID: 16151806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
    Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
    Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.